Replimune REPL
NASDAQ REPL
$15.03 -0.26 (-1.70%)
As of: Sep 4, 2026 · 12:49 PM EDT

Replimune (REPL) Operating Income (2017 - 2026)

Replimune (REPL) posted Operating Income of -$73.3 million for Q1 2026, down 2.05% sequentially from -$71.9 million in Q4 2025, and up 7.55% YoY from -$68.2 million in Q1 2025.

Analysis

Replimune (REPL) Operating Income (2017 - 2026) Analysis & Trends

Replimune has reported Operating Income for 10 years, with the latest figure at -$73.3 million in Q1 2026.

  • Quarterly Operating Income rose 7.55% year-over-year to -$73.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$319.9 million (down 22.28% YoY) and the FY2026 annual result came in at -$319.9 million, down 22.28% from the prior year.
  • Operating Income eased to -$73.3 million in Q1 2026 per REPL's latest filing, from -$71.9 million in the prior quarter.
  • Over five years, Operating Income peaked at -$32.0 million in Q1 2022 and troughed at -$90.4 million in Q2 2025.
  • A 5-year average of -$60.3 million and a median of -$58.8 million in 2024 frame the typical range for Operating Income.
  • The sharpest annual moves came in 2023 and 2024: Operating Income plunged 65.67% in 2023, then rose 7.7% in 2024.
  • Over 5 years, Operating Income stood at -$41.6 million in 2022, then sank by 35.82% to -$56.5 million in 2023, then dropped by 16.77% to -$66.0 million in 2024, then retreated by 8.86% to -$71.9 million in 2025, then fell by 2.05% to -$73.3 million in 2026.
  • According to Business Quant data, Operating Income over the past three periods registered -$73.3 million, -$71.9 million, and -$84.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Vertex Pharmaceuticals 139.76 Bn 131.91 Bn 2.84 Bn 1.25 Bn
2 Regeneron Pharmaceuticals 85.72 Bn 77.72 Bn 3.93 Bn 1.29 Bn
3 Argenx Se 63.56 Bn 58.38 Bn 1.37 Bn 493.00 Mn
4 Moderna 57.87 Bn 52.73 Bn 52.00 Mn -815.00 Mn
5 Revolution Medicines 44.06 Bn 44.06 Bn - -505.13 Mn
6 BeOne Medicines 40.08 Bn 34.98 Bn 1.53 Bn 325.05 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.20 Bn 992.69 Mn 231.44 Mn
8 Royalty Pharma 28.54 Bn 27.70 Bn - 133.12 Mn
9 Insmed 27.49 Bn 26.33 Bn 358.27 Mn -1.55 Mn
10 Replimune 1.46 Bn 1.46 Bn - -68.25 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -68.25 Mn
Mar 31, 2026 -73.34 Mn
Dec 31, 2025 -71.87 Mn
Sep 30, 2025 -84.29 Mn
Jun 30, 2025 -90.42 Mn
Mar 31, 2025 -79.33 Mn
Dec 31, 2024 -66.02 Mn
Sep 30, 2024 -58.92 Mn
Jun 30, 2024 -57.37 Mn
Mar 31, 2024 -58.76 Mn
Dec 31, 2023 -56.54 Mn
Sep 30, 2023 -63.83 Mn
Jun 30, 2023 -55.65 Mn
Mar 31, 2023 -53.00 Mn
Dec 31, 2022 -41.63 Mn
Sep 30, 2022 -41.58 Mn
Jun 30, 2022 -40.88 Mn
Mar 31, 2022 -31.99 Mn
Dec 31, 2021 -29.70 Mn
Sep 30, 2021 -29.25 Mn